Literature DB >> 25628103

Multistep tumorigenesis in peripheral T cell lymphoma.

Mamiko Sakata-Yanagimoto1.   

Abstract

Peripheral T cell lymphomas (PTCL) are classified as mature T cell neoplasms. However, several new findings support the notion that premalignant cells arise in the immature stage of hematopoietic differentiation, and subsequently evolve into full-blown T-lineage tumor cells. Acquisition of (Ten-Eleven Translocation 2) TET2 mutations may be an important event for the establishment of premalignant cells. In PTCL harboring features of follicular helper T cells, tumor-specific G17V RHOA mutations co-occur with premalignant TET2 mutations. The G17V (ras homolog family member A) RHOA mutations may play important roles in clonal evolution of premalignant cells into tumor cells. Indeed, multistep tumorigenesis is thought to be essential for pathogenesis of PTCL.

Entities:  

Keywords:  AITL; PTCL; RHOA; TET2

Mesh:

Substances:

Year:  2015        PMID: 25628103     DOI: 10.1007/s12185-015-1738-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  52 in total

Review 1.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

2.  Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA.

Authors:  Yu-Fei He; Bin-Zhong Li; Zheng Li; Peng Liu; Yang Wang; Qingyu Tang; Jianping Ding; Yingying Jia; Zhangcheng Chen; Lin Li; Yan Sun; Xiuxue Li; Qing Dai; Chun-Xiao Song; Kangling Zhang; Chuan He; Guo-Liang Xu
Journal:  Science       Date:  2011-08-04       Impact factor: 47.728

Review 3.  Epigenetic aspects of MDS and its molecular targeted therapy.

Authors:  Jumpei Yamazaki; Jean-Pierre J Issa
Journal:  Int J Hematol       Date:  2012-10-10       Impact factor: 2.490

4.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

5.  Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age.

Authors:  L Busque; R Mio; J Mattioli; E Brais; N Blais; Y Lalonde; M Maragh; D G Gilliland
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

Review 6.  IDH mutations in glioma and acute myeloid leukemia.

Authors:  Lenny Dang; Shengfang Jin; Shinsan M Su
Journal:  Trends Mol Med       Date:  2010-08-05       Impact factor: 11.951

7.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

Review 8.  Gene mutations of acute myeloid leukemia in the genome era.

Authors:  Tomoki Naoe; Hitoshi Kiyoi
Journal:  Int J Hematol       Date:  2013-01-29       Impact factor: 2.490

9.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

View more
  14 in total

Review 1.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

Review 2.  Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma.

Authors:  Manabu Fujisawa; Shigeru Chiba; Mamiko Sakata-Yanagimoto
Journal:  J Clin Exp Hematop       Date:  2017

Review 3.  Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category.

Authors:  Mamiko Sakata-Yanagimoto; Kota Fukumoto; Kennosuke Karube; Shigeru Chiba
Journal:  J Clin Exp Hematop       Date:  2021-03-15

Review 4.  Molecular Pathogenesis of Peripheral T Cell Lymphoma.

Authors:  Mamiko Sakata-Yanagimoto; Shigeru Chiba
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 4.213

5.  Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma.

Authors:  Mathijs Willemsen; Harry C Schouten
Journal:  Biomark Res       Date:  2017-02-08

6.  Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.

Authors:  M Fujisawa; M Sakata-Yanagimoto; S Nishizawa; D Komori; P Gershon; M Kiryu; S Tanzima; K Fukumoto; T Enami; M Muratani; K Yoshida; S Ogawa; K Matsue; N Nakamura; K Takeuchi; K Izutsu; K Fujimoto; T Teshima; H Miyoshi; P Gaulard; K Ohshima; S Chiba
Journal:  Leukemia       Date:  2017-08-23       Impact factor: 11.528

7.  ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma.

Authors:  Yalu Liu; Xiaogan Wang; Lijuan Deng; Lingyan Ping; Yunfei Shi; Wen Zheng; Ningjing Lin; Xiaopei Wang; Meifeng Tu; Yan Xie; Weiping Liu; Zhitao Ying; Chen Zhang; Zhengying Pan; Xi Wang; Ning Ding; Yuqin Song; Jun Zhu
Journal:  Cancer Cell Int       Date:  2019-02-14       Impact factor: 5.722

Review 8.  Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.

Authors:  Ping Zhang; Mingzhi Zhang
Journal:  Clin Epigenetics       Date:  2020-11-07       Impact factor: 6.551

Review 9.  Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma.

Authors:  Kota Fukumoto; Tran B Nguyen; Shigeru Chiba; Mamiko Sakata-Yanagimoto
Journal:  Cancer Sci       Date:  2017-11-27       Impact factor: 6.518

10.  EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma.

Authors:  Ahmed E Eladl; Kazuyuki Shimada; Yuka Suzuki; Taishi Takahara; Seiichi Kato; Kei Kohno; Ahmed Ali Elsayed; Chun-Chieh Wu; Takashi Tokunaga; Tomohiro Kinoshita; Mamiko Sakata-Yanagimoto; Shigeo Nakamura; Akira Satou
Journal:  Cancer Med       Date:  2019-12-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.